Project 2: PanbetaCoV protein vaccine design
项目2:PanbetaCoV蛋白疫苗设计
基本信息
- 批准号:10327524
- 负责人:
- 金额:$ 421.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-16 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAddressAdjuvantAlphavirusAnimal ModelAnimalsAntibodiesAntibody ResponseAntibody titer measurementAntigensAvidityBindingCOVID-19 vaccineCell surfaceChiropteraComplexCoronavirusCoronavirus spike proteinCryoelectron MicroscopyDevelopmentDisease OutbreaksEnsureEpitopesFerritinFollicular Dendritic CellsFutureGoalsHIVHIV vaccineHealthHumanImmunityImmunizeImmunologic MonitoringInfluenzaMacacaMediatingMessenger RNAMethodsMiddle East Respiratory SyndromeMolecular ConformationMusMutationPeptidesProteinsSARS coronavirusSiteStructureStructure of germinal center of lymph nodeSurfaceSystemTechniquesTestingTherapeuticTranslatingVaccine DesignVaccinesVariantViralWild Type MouseWorkaluminum sulfatebasebetacoronavirusbetacoronavirus vaccinecross reactivitydesignexpectationimmunogenicinfluenza virus vaccinelipid nanoparticlenanoparticleneutralizing antibodynonhuman primatenovelpandemic diseasepandemic preparednessphase III trialpreventprogramsprotein structurereceptor bindingresearch clinical testingspillover eventtraffickingvaccine candidatevaccine developmentvaccine-induced antibodieszoonotic coronavirus
项目摘要
Abstract – Project 2
Animal betacoronaviruses (betaCoVs), such as those that gave rise to SARS-CoV-1, MERS, and now SARS-
CoV-2, represent a significant, continuous threat to human health. Vaccines can provide pre-existing immunity
to future zoonotic coronaviruses. A major limitation of the current effective vaccines to SARS-CoV-2 is that they
likely will only protect SARS-CoV-2 isolates that are nearly identical to the Wuhan isolate used in the
vaccines. Thus, the world remains vulnerable to SARS-CoV-2 mutational escape variants
and from future animal betacoronavirus spillover events that have pandemic potential. Vaccine development
that addresses this vulnerability is urgently needed. Project 2 will support this Program’s overall goal to develop
vaccines that will prevent future betaCoV pandemics and SARS-CoV-2 escape variants by
designing vaccine immunogens that elicit broadly neutralizing antibodies (bnAb) to provide protective
immunity across the betaCoV genus. Structurally conserved neutralizing epitopes exist
on betaCoV spike proteins, and we hypothesize that vaccines that elicit broadly protective antibodies to these
sites can be developed. In preliminary studies, we have isolated cross-reactive neutralizing antibodies from
SARS-CoV-1 or SARS-CoV-2-infected or recovered humans and used structural determination to precisely
define their betaCoV bnAb epitopes. Our vaccine design strategy involves using computational and structural-
based design techniques to develop immunogens that preferentially present these and additionally
identified bnAb epitopes. Each immunogen design will be displayed on the surface of nanoparticles to enhance
antigen avidity and antigen trafficking to germinal centers and follicular dendritic cells. We have demonstrated a
proof-of-concept for our strategy using a multimerized SARS-CoV-2 receptor binding domain (RBD)-
ferritin nanoparticle that induces high titers of antibodies that neutralize diverse human and
animal Sarbecoviruses (group 2b) in immunized macaques. In Aim 1, we will isolate new antibodies to define
additional bnAb epitopes and establish the full spectrum of regions on the surface of betaCoV S proteins that
are capable of inducing bnAbs to animal betaCoVs in groups 2b and 2c. In Aim 2, we will utilize cutting-edge
computational immunogen design methods to design broadly neutralizing epitope-focused immunogens. These
immunogens have the spike protein fixed in conformations that expose neutralizing epitopes or are spike
subunits that are truncated or resurfaced to remove irrelevant, non-neutralizing, or betaCoV strain-specific
neutralizing epitopes while retaining broadly neutralizing epitopes. In Aim 3, we will immunize wild-type mice
with these novel immunogens and evaluate their ability to induce human betaCoV bnAbs that can protect
animals from viral challenge. Project 2 will impact the field by generating cross-reactive neutralizing antibodies
that could be translated into therapeutics, elucidating new broadly neutralizing epitopes on the betaCoV spike
protein, and defining the design principles for epitope-focused immunogens that elicit protective immunity
to betaCoVs.
摘要-项目2
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin Wiehe其他文献
Kevin Wiehe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin Wiehe', 18)}}的其他基金
Project 2: PanbetaCoV protein vaccine design
项目2:PanbetaCoV蛋白疫苗设计
- 批准号:
10842503 - 财政年份:2021
- 资助金额:
$ 421.74万 - 项目类别:
Immunogen design to elicit polyclonal bNAb responses to the V3 glycan supersite
免疫原设计引发对 V3 聚糖超级位点的多克隆 bNAb 反应
- 批准号:
10631904 - 财政年份:2017
- 资助金额:
$ 421.74万 - 项目类别:
Immunogen design to elicit polyclonal bNAb responses to the V3 glycan supersite
免疫原设计引发对 V3 聚糖超级位点的多克隆 bNAb 反应
- 批准号:
10370985 - 财政年份:2017
- 资助金额:
$ 421.74万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 421.74万 - 项目类别:
Research Grant